BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24916639)

  • 1. Interleukin-17 receptor expression on vascular endothelial cells of masses of skeletal extramedullary disease in myeloma patients.
    Yang JZ; Li Y; Sun LX; Fang J; Kong LJ; Zhang JQ
    Pathol Res Pract; 2014 Sep; 210(9):586-90. PubMed ID: 24916639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival.
    Yang JZ; Lian WG; Sun LX; Qi DW; Ding Y; Zhang XH
    Pathol Res Pract; 2016 Mar; 212(3):210-6. PubMed ID: 26774288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of increased microvessel density with skeletal extramedullary disease relapse in multiple myeloma patients who have skeletal extramedullary disease at diagnosis.
    Yang JZ; Wu XD; Meng JB; Zhang JQ; Sun LX
    Pathol Res Pract; 2018 Oct; 214(10):1694-1699. PubMed ID: 30196985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.
    Kline M; Donovan K; Wellik L; Lust C; Jin W; Moon-Tasson L; Xiong Y; Witzig TE; Kumar S; Rajkumar SV; Lust JA
    Leuk Res; 2007 May; 31(5):591-8. PubMed ID: 16879867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis.
    Belloni D; Marcatti M; Ponzoni M; Ciceri F; Veschini L; Corti A; Caligaris Cappio F; Ferrarini M; Ferrero E
    Exp Cell Res; 2015 Jan; 330(1):1-12. PubMed ID: 25447443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment.
    Bolkun L; Lemancewicz D; Sobolewski K; Mantur M; Semeniuk J; Kulczynska A; Kloczko J; Dzieciol J
    Adv Med Sci; 2013; 58(1):118-25. PubMed ID: 23333895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gene expression of vascular endothelial growth factors and their receptors in different variants of the course of multiple myeloma].
    Golenkov AK; Buravtsova IV; Dudina GA; Lutskaia TD; Mitina TA; Kataeva EV; Karamysheva AF; Kakpakova ES; Sablina IuA; Stavrovskaia AA
    Ter Arkh; 2013; 85(7):98-102. PubMed ID: 24137956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis.
    Ribatti D; Nico B; Vacca A
    Int Rev Cell Mol Biol; 2015; 314():259-82. PubMed ID: 25619720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
    Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
    Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
    Bellamy WT; Richter L; Frutiger Y; Grogan TM
    Cancer Res; 1999 Feb; 59(3):728-33. PubMed ID: 9973224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis.
    Carrai V; Miniati I; Guiducci S; Capaccioli G; Alterini R; Saccardi R; Conforti ML; Rigacci L; Rotunno G; Bosi A; Cerinic MM
    Rheumatology (Oxford); 2012 Jun; 51(6):1042-8. PubMed ID: 22271757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.